Taysha Gene Therapies, Inc. - Common Stock (TSHA) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
TSHA on Nasdaq
Shares outstanding
274,650,631
Price per share
$5.50
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
264,427,699
Total reported value
$864,676,435
% of total 13F portfolios
0.01%
Share change
+6,900,092
Value change
+$29,349,050
Number of holders
150
Price from insider filings
$5.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock (TSHA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $90,456,313 +$7,574,932 27,662,481 +9.1% RA Capital Management, L.P. 30 Sep 2025
Manning Paul B 9.8% $59,394,578 25,601,111 Paul B Manning 30 May 2025
RTW INVESTMENTS, LP 9.9% -0.9% $66,483,878 +$11,906,347 25,183,287 +22% RTW Investments, LP 30 Jun 2025
BlackRock, Inc. 6.5% +26% $98,187,600 +$25,844,308 17,852,291 +36% BlackRock, Inc. 31 Dec 2025
MORGAN STANLEY 6.7% -21% $44,506,820 -$2,034,437 16,858,644 -4.4% Morgan Stanley 30 Jun 2025
FMR LLC 6.2% -22% $41,257,450 -$1,947,903 15,627,822 -4.5% FMR LLC 30 Jun 2025
GOLDMAN SACHS GROUP INC 5.1% $33,274,806 12,748,968 THE GOLDMAN SACHS GROUP, INC. 26 Jun 2025
Octagon Capital Advisors LP 3.3% -36% $29,650,725 -$4,520,775 9,067,500 -13% Octagon Capital Advisors LP 30 Sep 2025

As of 30 Sep 2025, 150 institutional investors reported holding 264,427,699 shares of Taysha Gene Therapies, Inc. - Common Stock (TSHA). This represents 96% of the company’s total 274,650,631 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Taysha Gene Therapies, Inc. - Common Stock (TSHA) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 8.9% 24,354,291 -2.7% 0.98% $79,638,532
RA CAPITAL MANAGEMENT, L.P. 8.6% 23,555,648 0% 0.95% $77,026,969
Avoro Capital Advisors LLC 7.9% 21,700,000 0% 0.92% $70,959,000
MORGAN STANLEY 7% 19,307,603 +14% 0% $63,135,862
BlackRock, Inc. 6% 16,364,861 +23% 0% $53,513,096
FMR LLC 5.3% 14,593,412 -6.6% 0% $47,720,458
GOLDMAN SACHS GROUP INC 4.9% 13,383,708 +6.3% 0.01% $43,764,725
VANGUARD GROUP INC 4.7% 12,849,613 +18% 0% $42,018,234
Siren, L.L.C. 4% 11,014,737 0% 1.4% $36,018,190
Octagon Capital Advisors LP 3.3% 9,067,500 -28% 4.6% $29,650,725
Point72 Asset Management, L.P. 2.7% 7,331,470 +0.19% 0.05% $23,973,907
STATE STREET CORP 2.6% 7,236,465 +41% 0% $23,663,241
Vestal Point Capital, LP 2% 5,500,000 +83% 0.82% $17,985,000
DEERFIELD MANAGEMENT COMPANY, L.P. 2% 5,386,000 0% 0.27% $17,612,220
Polar Capital Holdings Plc 1.9% 5,293,879 +5.9% 0.08% $17,310,984
GEODE CAPITAL MANAGEMENT, LLC 1.9% 5,174,516 +36% 0% $16,924,446
BARCLAYS PLC 1.9% 5,148,112 +1043% 0.01% $16,834,325
MILLENNIUM MANAGEMENT LLC 1.5% 4,026,122 +37% 0.01% $13,165,419
BAKER BROS. ADVISORS LP 1.5% 4,004,756 0% 0.09% $13,095,552
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 1.3% 3,700,000 -9.6% 39% $12,099,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.2% 3,328,000 -31% 0.02% $10,882,560
Affinity Asset Advisors, LLC 1.1% 3,000,000 +1400% 0.91% $9,810,000
ADAR1 Capital Management, LLC 1% 2,835,680 -5.8% 0.92% $9,272,674
D. E. Shaw & Co., Inc. 0.99% 2,706,434 +574% 0.01% $8,850,039
Jefferies Financial Group Inc. 0.79% 2,156,642 -79% 0.06% $7,052,219

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock (TSHA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,625,224 $14,438,321 +$13,180,203 $5.50 13
2025 Q3 264,427,699 $864,676,435 +$29,349,050 $3.27 150
2025 Q2 257,684,976 $595,324,582 +$211,768,578 $2.31 147
2025 Q1 166,761,354 $231,855,383 -$5,171,826 $1.39 124
2024 Q4 167,381,791 $289,604,775 +$18,983,312 $1.73 126
2024 Q3 156,893,147 $315,365,141 -$17,620,277 $2.01 114
2024 Q2 158,086,076 $354,139,573 +$33,881,138 $2.24 102
2024 Q1 140,148,555 $402,080,424 +$33,453,660 $2.87 106
2023 Q4 130,129,882 $230,288,972 -$12,329,934 $1.77 85
2023 Q3 129,862,060 $410,364,849 +$376,246,041 $3.16 59
2023 Q2 13,698,356 $9,051,371 -$2,014,707 $0.66 37
2023 Q1 16,687,605 $13,286,354 -$3,025,814 $0.80 42
2022 Q4 19,375,255 $43,785,515 +$12,385,904 $2.26 51
2022 Q3 13,927,007 $27,020,000 -$1,811,564 $1.93 48
2022 Q2 14,700,530 $54,695,000 -$11,594,670 $3.72 55
2022 Q1 17,015,055 $110,894,239 -$16,224,000 $6.52 70
2021 Q4 18,503,286 $215,562,592 -$15,412,583 $11.65 64
2021 Q3 19,436,846 $361,910,267 +$4,396,852 $18.62 48
2021 Q2 18,320,557 $388,394,891 +$15,022,269 $21.20 48
2021 Q1 17,661,042 $358,518,075 -$11,587,017 $20.30 46
2020 Q4 17,998,551 $475,216,635 +$32,037,839 $26.54 51
2020 Q3 16,580,732 $366,712,000 +$366,712,000 $22.40 46